Nadia Iovieno, MD

  • 11Articles
  • 70.5KReads
  • 2011–2022Active
  • 32Collaborators
  • 1.3KCitations

About

Nadia Iovieno, MD, is affiliated with the Clinical Trials Network and Institute, Department of Psychiatry at Massachusetts General Hospital, and the Department of Psychiatry at Harvard Medical School. Her publications from 2011 to 2022 focus on major depressive disorder (MDD), including clinical trials and meta-analyses of treatments such as intranasal esketamine, vortioxetine, ziprasidone augmentation, and pramipexole. She has also examined placebo responses, demographic and design variables in depression studies, and antidepressant efficacy in late-life depression and comorbid alcohol use disorders. Frequent collaborators include George I. Papakostas, Maurizio Fava, and Dan V. Iosifescu.

Publications

JCP
Rapidity of Improvement With Intranasal Esketamine for MDD
Meta-Analysis

Rapidity of Improvement With Intranasal Esketamine for MDD

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.
, , , et al
JCP
Meta-Analysis

Vortioxetine for Major Depressive Disorder

June 15, 2021

Prior meta-analyses have found vortioxetine to be efficacious for depression. Building on those findings, the present meta-analysis examined the effect that placebo response has on drug-placebo effect size in...
, , , et al
JCP
Original Research

Ziprasidone Augmentation of Escitalopram for Cognition

July 25, 2017

Cognitive deficits are common in depression, but studies suggest that cognitive dysfunction is difficult to treat with antidepressants. Can adding an atypical antipsychotic medication to antidepressant treatment help lessen...
, , , et al
JCP
Meta-Analysis

Monotherapy in Mood Disorders

May 25, 2016

Is one drug good enough? Read this review of 215 double-blind, randomized, placebo-controlled trials to discover which monotherapies have overall short-term efficacy in treating MDD and bipolar depression.
, , , et al
JCP
Review Article

The Nature of Placebo Response in Clinical Studies of Major Depressive Disorder

February 3, 2015

, ,
JCP
Original Research

A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder

July 15, 2013

, , , et al
JCP
Review Article

Correlation Between Different Levels of Placebo Response Rate and Clinical Trial Outcome in Major Depressive Disorder: A Meta-Analysis

October 15, 2012

,
JCP
Review Article

Does the Presence of an Open-Label Antidepressant Treatment Period Influence Study Outcome in Clinical Trials Examining Augmentation/Combination Strategies in Treatment Partial Responders/Nonresponders With Major Depressive Disorder?

April 3, 2012

,
JCP
Article

Efficacy of Antidepressants for Late-Life Depression: A Meta-Analysis and Meta-Regression of Placebo-Controlled Randomized Trials

December 15, 2011

, , , et al
JCP
ASCP Corner

Assessing the Adequacy of Past Antidepressant Trials: A Clinician's Guide to the Antidepressant Treatment Response Questionnaire

August 15, 2011

, , , et al
JCP
Article

Antidepressants for Major Depressive Disorder and Dysthymic Disorder in Patients With Comorbid Alcohol Use Disorders: A Meta-Analysis of Placebo-Controlled Randomized Trials

April 19, 2011

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe